Cardiomyopathy | Medscape Cardiomyopathy | Medscape
Review in-depth clinical information, latest medical news, and guidelines for management of various types of cardiomyopathy, including viral cardiomyopathy, infiltrative cardiomyopathy, postpartum cardiomyopathy, obstructive cardiomyopathy, primary cardiomyopathy, or idiopathic cardiomyopathy. Read articles about causes of cardiomyopathy symptoms and cardiomyopathy treatment. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 8, 2020 Category: Consumer Health News Tags: Resource Center Source Type: news
Fat cells found to play a central role in renal failure-associated cardiomyopathy
(Marshall University Joan C. Edwards School of Medicine) New research from a team at the Marshall University Joan C. Edwards School of Medicine reveals the central role of fat cells in the systemic oxidant stress observed in renal failure-associated cardiomyopathy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2020 Category: International Medicine & Public Health Source Type: news
Towbin receives National Institutes of Health research project grant
(Le Bonheur Children's Hospital) Jeffrey A. Towbin, MD, of Le Bonheur Children's Hospital and the University of Tennessee Health Science Center was awarded a Research Project Grant (R01) from the National Institutes of Health (NIH) with co-principal investigators Enkhsaikha Purevjav, MD, PhD and Lu Lu, MD, MS. He is lead principal investigator on the project 'Discovery of Modifier Genes in Cardiomyopathy..' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2020 Category: International Medicine & Public Health Source Type: news
Emergency in a Dilated Cardiomyopathy Patient Emergency in a Dilated Cardiomyopathy Patient
A 76-year-old woman with dilated cardiomyopathy has a rapid heart rate associated with hypotension. What does her ECG show?Medscape Cardiology (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 18, 2020 Category: Cardiology Tags: Cardiology Clinical Case Source Type: news
High-Dose Tafamidis Boosts Survival in Cardiomyopathy High-Dose Tafamidis Boosts Survival in Cardiomyopathy
Tafamidis provided a significantly greater survival benefit in patients with transthyretin amyloid cardiomyopathy in the long-term extension of the landmark ATTR-ACT trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 9, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Is Takotsubo Cardiomyopathy A Heart Attack
Is Takotsubo Cardiomyopathy a Heart Attack? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 9, 2020 Category: General Medicine Source Type: news
Hypertrophic Cardiomyopathy
What Is the Life Expectancy of Someone with Hypertrophic Cardiomyopathy? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 8, 2020 Category: General Medicine Source Type: news
PKCdelta causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction
Sepsis-induced cardiomyopathy (SIC) is associated with increased patient mortality. At present, there are no specific therapies for SIC. Previous studies have reported increased reactive oxygen species (ROS) and mitochondrial dysfunction during SIC. However, a unifying mechanism remains to be defined. We hypothesized that PKCdelta is required for abnormal calcium handling and cardiac mitochondrial dysfunction during sepsis and that genetic deletion of PKCdelta would be protective. Polymicrobial sepsis induced by cecal ligation and puncture (CLP) surgery decreased the ejection fraction of wild-type (WT) mice but not PKCdelt...
Source: Current Awareness Service for Health (CASH) - June 4, 2020 Category: Consumer Health News Source Type: news
Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know
Although it is the most common inherited monogenic cardiac disorder, affecting up to 0.5% of the population, there is a gap in the recognition of this condition.ACC.org (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 22, 2020 Category: Cardiology Tags: Cardiology Article Source Type: news
Functional Gains From Novel Agent for OHCM, Top-line Results Functional Gains From Novel Agent for OHCM, Top-line Results
Patients with obstructive hypertrophic cardiomyopathy showed consistent hemodynamic and functional gains on mavacamten, which targets cardiac myosin, in top-line results released by MyoKardia.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Peninsula heart drug maker soars on positive late-stage clinical trial
Aiming to ask regulators early next year to approve its treatment for a potentially fatal heart condition, a Peninsula company's stock jumped more than 70% today on news that its drug passed a critical late-stage clinical trial.
MyoKardia Inc. (NASDAQ: MYOK) of Brisbane said early data from a 251-patient, Phase III clinical trial indicates that people with a heart condition known as symptomatic, obstructive hypertrophic cardiomyopathy, or HCM, who were given the drug mavacamten over 30 weeks saw… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 11, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Peninsula heart drug maker soars on positive late-stage clinical trial
Aiming to ask regulators early next year to approve its treatment for a potentially fatal heart condition, a Peninsula company's stock jumped more than 70% today on news that its drug passed a critical late-stage clinical trial.
MyoKardia Inc. (NASDAQ: MYOK) of Brisbane said early data from a 251-patient, Phase III clinical trial indicates that people with a heart condition known as symptomatic, obstructive hypertrophic cardiomyopathy, or HCM, who were given the drug mavacamten over 30 weeks saw… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 11, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
Untangling the Physiology of Transthyretin Cardiac Amyloidosis Untangling the Physiology of Transthyretin Cardiac Amyloidosis
A new study investigates echocardiographic phenotypes of transthyretin cardiac amyloidosis, the most common etiology of restrictive cardiomyopathy, identifying parameters predictive of survival.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 11, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Connecting the dots between heart disease, potential for worse COVID-19 outcomes
(Mayo Clinic) People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease ? obstructive hypertrophic cardiomyopathy (HCM) ? the heart increases production of the ACE2 RNA transcript and the translated ACE2 protein. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2020 Category: Infectious Diseases Source Type: news
Physicians, scientists and physician-scientists connect dots between heart disease, potential for worse COVID-19 outcomes
ROCHESTER, Minn. ? People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease ? obstructive hypertrophic cardiomyopathy (HCM) ? the heart increases production of the ACE2 RNA transcript [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2020 Category: Databases & Libraries Source Type: news
